Replies to post #250515 on Biotech Values

[tony111]

I own a lot of MOR since I was invested in constellation pharma for pelabresib. Personally I think its lead drug pelabresib is worth a lot more than just 2.7B dollars. I can't believe Incyte pass on this. Future first line SOC for myelofibrosis will be momelotinib+pelabresib.